The adrenocorticotrophic effects of a synthetic corticotrophin analogue, al-18 ACTH with D-serinel, lysine17, and lysine widel8 substitutions has been studied. It is effective after both intramuscular and subcutaneous administration and compared with tetracosactrin depot (Synacthen depot, Cortrosyn depot) it has a similarly prolonged time course of action-about 24 hours after 0-5 mg and 30 hours after 1 mg. Unlike tetracosactrin depot, however, it is well absorbed when given intranasally and does not produce painful reactions at the site of injection. Its prolonged time course of action does not depend on a formulation designed to delay its release from the injection site but most probably on a decreased rate of degradation in the circulation.
Introduction
Tetracosactrin (al-24 ACTH,* Synacthen, Cortrosyn) is a synthetic polypeptide containing the first 24 amino-acids of ACTH in a sequence which is identical with that of all species so far fully investigated. It has potent corticotrophic properties but a length of action of only four to five hours when used in an unmodified form (Landon et al., 1964) . In order to produce a therapeutically useful preparation tetracosactrin has been adsorbed on to zinc phosphate to delay its absorption from the site of injection (tetracosactrin depot, Synacthen depot, Cortrosyn depot) and the adrenocorticotrophic actions of this compound last for 24 to 48 hours after an intramuscular injection of 1 mg (Besser et al., 1967; Nelson et al., 1968; Haupt et al., 1969; Treadwell and Dennis, 1969) . However, this preparation may produce painful local reactions if given subcutaneously or sometimes intramuscularly (Besser et al., 1967; Nelson et al., 1968; Treadwell and Dennis, 1969) , and this seems to be due to the contained zinc complexes. Occasionally generalized allergic reactions after tetracosactrin depot occur though in general it can be used in patients who are hypersensitive to animal ACTH (El-Shaboury, 1968; Jensen and Sneddon, 1969 ).
An altemative corticotrophic polypeptide has been synthesized (Desaulles et al., 1969) which has a prolonged therapeutically useful time course of action without the addition of any agent to delay its absorption. The prolonged action results from modification of the ACTH peptide sequence and is presumably due to delayed degradation in the circulation. The polypeptide consists of the first (N-terminal) 18 aminoacids of natural ACTH with the following substitutions: D-* The ACTH nomenclature of Li (1959) This peptide is referred to as al-l8 ACTH in this paper. We now report the potency and length of action of this compound after intramuscular, subcutaneous, intranasal, and sublingual administration to normal subjects.
Methods and Subjects
There were 12 normal subjects aged 20 to 40 years (2 were women). Intramuscular injections into the buttock of 0-5 and 1 mg and subcutaneous injections of 0.5 mg of al-18 ACTH were compared in the same six subjects who had been given oral dexamethasone to suppress their endogenous ACTH secretion. The dexamethasone was given in a dose of 2 mg on retiring before and on waking on the day of the study, and then 1 mg each six hours until the blood sampling was complete. The three treatments were given according to a randomized Latin square design at intervals of at least seven days. Intranasal administration was given to six other subjects who had not taken dexamethasone, a pressurized insufflator being used to deliver 0-9 mg of al-18 ACTH as a powder in three doses.
Sublingual al-18 ACTH (0.5 and 1 mg) was administered in gelatin lozenges to two subjects who had received oral dexamethasone as above.
The drug was given between 9 and 10 a.m. and blood was sampled before and at intervals for 30 hours afterwards. Plasma corticosteroids were measured by a fluorometric technique (Mattingly, 1962) . The changes in corticosteroids from the starting control levels were calculated and the differences in the means at each time interval were compared with Student's t test (2-tailed). In addition, the maximum changes in plasma corticosteroids after each treatment, irrespective of the time interval at which they occurred, were calculated and the means compared.
Results
After intramuscular injection of 1 mg of al-18 ACTH the mean plasma fluorogenic corticosteroid concentration rose by 45+S.E. 4.7 ,ug/100 ml to reach a peak at six hours and then l BRITISH MEDICAL JOURNAL 25 SEPTEMBER 1971 743 returned to the baseline in a little over 30 hours (Fig. 2) . After 0-5 mg the mean corticosteroid level rose by 37+2-7 ,ug/ 100 ml, reaching a peak at two hours, and remained raised for about 24 hours. After subcutaneous injections of 0-5 mg of a1-18 ACTH the mean plasma corticosteroids rose by 30 + 1-9 ,tg/ 100 ml at two hours and returned to the baseline values between 16 and 20 hours. After intranasal administration (0-9 mg) the material was well absorbed and the mean plasma corticosteroids rose rapidly, reaching a peak at four hours of 37 + 3.7 ,g/100 ml above the mean control value and remained raised for about 24 hours. Sublingual administration of a1-18 ACTH did not result in any rise in plasma corticosteroids in Comparison of Routes of Administration.-There was no significant difference between the mean maximum increments in corticosteroids achieved after 1 mg of al-18 ACTH given intramuscularly and 0-9 mg given intranasally. However, the mean plasma corticosteroid increments were consistently lower after intranasal administration over the whole time course of action. The overall time courses of the compound administered both ways were the same, since the increment at 24 hours after the intramuscular dose was 10+6-0 ug/100 ml and after the intranasal dose 6+6±3 ,ug/100 ml and these were not significantly different. When the effects of 0.5 mg of al-18 ACTH were compared the peak increments did not differ significantly whether the doses were given intramuscularly or subcutaneously (P just greater than 0 05). After the peak, however, the mean corticosteroid increments were lower after subcutaneous administration and the time course was shorter than after the intramuscular dose. The mean corticosteroid increments were virtually identical after 0.5 mg given intramuscularly and 0.9 mg given intranasally.
Side Effects.-Side effects were not encountered after administration of a!l-l8 ACTH when given intramuscularly or intranasally. When given subcutaneously two out of six subjects experienced a transient vascular flare at the site of the injection but there was no pain or induration.
Discussion
The corticotrophin analogue a1-18 ACGH with D-serinel, lysine17, and lysine amidelg substitutions (Fig. 1) has been shown to be rapidly and effectively absorbed whether administered intramuscularly, subcutaneously, or intranasally but not from the buccal mucosa. There were no unpleasant side effects. It seems that the compound would be therapeutically valuable since it has a prolonged corticotrophic action-24 hours after 0-5 mg and 30 hours after 1 mg when given intramuscularly. These studies confirm the preliminary observations of Felber et al. (1969) and Walser et al. (1969) . The prolonged effects are achieved by the modifications of the peptide sequence of natural ACTH designed to delay its degradation in the body, and hence a formulation to produce slow release from the site of injection is not required. A similarly prolonged time course is achieved when it is absorbed from the nasal mucosa.
The increments in plasma corticosteroids after intranasal administration are probably underestimated at four and eight hours after the dose, since the subjects in this group were not dexamethasone suppressed. The plasma corticosteroids normally decline during the second half of the day and would be expected to be 6 to 10 ,ug/100 ml lower than in the moming, but we have subtracted the control 9 a.m. pretreatment values from each subject's subsequent corticosteroid levels as control plasmas were not obtained later in the day.
The results contrast with those reported after tetracosactrin, for the length of action of this compound is only four to five hours after a 0'5-mg dose given intramuscularly (Landon et al., 1964) or 1-5 mg intranasally (Keenan and Chamberlain, 1969) , and to obtain a therapeutically useful duration of action this polypeptide was absorbed on to zinc phosphate to delay its absorption from the site of injection. This preparation of tetracosactrin cannot be given intranasally and produces painful reactions when injected subcutaneously or into muscles of small bulk (Besser et al., 1967; Nelson et al., 1968) . The length of action of al-18 ACTH is very similar to that of tetracosactrin depot despite the lack of a delayed-release formulation.
We conclude that al-18 ACTH has advantages over tetracosactrin depot since it can be effectively administered subcutaneously and intranasally as well as intramuscularly without adverse local reactions, yet is equally potent and has a similar length of action.
